ArticleScience translational medicine2024
Antigenic distance between primary and secondary dengue infections correlates with disease risk.
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 20 citations in OpenAlex.
- Quantitative and qualitative differences in anti-Envelope IgG-secreting cells distinguish subclinical and hospitalized dengue in a Cambodian pediatric cohort.PLoS pathogens · 2026Article
- Association of dengue severity with the serotype of infection: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue.EMBO molecular medicine · 2026Article
- Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.Vaccine · 2026Article
- Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.medRxiv : the preprint server for health sciences · 2026Article
- Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes.PLoS neglected tropical diseases · 2026Article
- Purinergic signaling in dengue infection: modulation of P2 receptors as a potential therapeutic strategy.Purinergic signalling · 2026Review
- Scaling up efforts to target evolving viruses.eLife · 2026Article
- Genomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia.Cell reports · 2026Article
- Emergence of Two New Lineages of the Cosmopolitan Dengue Virus Serotype 2 in Yunnan, China, 2024.The Journal of infectious diseases · 2026Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Climate variation and serotype competition drive dengue outbreak dynamics in Singapore.Nature communications · 2025Article
- Genomic epidemiology of dengue virus 2 and 3 reveals repeated introductions and exportations of several lineages in Colombia.medRxiv : the preprint server for health sciences · 2025Article
- Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection.Pediatric investigation · 2025Review
- Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue.Cell host & microbe · 2025Article
- Article
- Review
- Eco-evolutionary dynamics of pathogen immune-escape: deriving a population-level phylodynamic curve.Journal of the Royal Society, Interface · 2025Article
- Molecular Epidemiology of Dengue Viruses in Lao People's Democratic Republic, 2020-2023.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 4 countries.
Funding
Abstract
Many pathogens continuously change their protein structure in response to immune-driven selection, resulting in weakened protection even in previously exposed individuals. In addition, for some pathogens, such as dengue virus, poorly targeted immunity is associated with increased risk of severe disease through a mechanism known as antibody-dependent enhancement. However, it remains unclear whether the antigenic distances between an individual's first infection and subsequent exposures dictate disease risk, explaining the observed large-scale differences in dengue hospitalizations across years. Here, we develop a framework that combines detailed antigenic and genetic characterization of viruses with details on hospitalized cases from 21 years of dengue surveillance in Bangkok, Thailand, to identify the role of the antigenic profile of circulating viruses in determining disease risk. We found that the risk of hospitalization depended on both the specific order of infecting serotypes and the antigenic distance between an individual's primary and secondary infections, with risk maximized at intermediate antigenic distances. These findings suggest that immune imprinting helps determine dengue disease risk and provide a pathway to monitor the changing risk profile of populations and to quantifying risk profiles of candidate vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.